First closing of Creathor Venture Fund III, with over € 50 million
"The first closing of our third fund is already well above the expected minimum size and thus almost at the level of the predecessor fund", says Dr. Gert Köhler, Managing Partner of Creathor Venture.
The investment focus is aimed at outstanding high-tech companies with an innovative business concept in rapidly growing high-technology markets such as mobile, social media, cleantech and life science. The regional focus is on Germany, France, Austria and Switzerland. As lead investor Creathor Venture generally holds a significant share, in average of about 30%, in its portfolio companies from the early phase up to the EXIT. The companies are actively managed.
Investors include family offices, fund of funds, entrepreneurs, the European Investment Fund and the European Union through which the Creathor Venture receives funding, originating from the
"Competitiveness and Innovation Framework Program (CIP)". The high commitment of the Fund's own management with the amount of € 15 million (in this fund) underlines the high confidence and entrepreneurial orientation.
"We are convinced of the positive environment that offers limited competition for attractive investment opportunities at favourable entry conditions," adds Dr. Gert Köhler.
Following the successful first closing, Creathor Venture expects to raise in due course a total of at least € 80 million for the final closing.
About Creathor Venture Management GmbH
Creathor venture currently manages a fund volume of more than € 150 million. The management members of Creathor Venture are the founder of the former Technologieholding VC GmbH, Dr.
Gert Köhler, Ingo Franz and Karl Heinz Schmelig. The team is over 20 years successfully active in Seite 2 von 2 early-stage venture capital business. Since then, more than 200 technology companies were funded, over 20 companies where listed on international stock exchanges (IPO) and several companies where sold. Above-average fund returns for the investors were achieved in this connection.
Weitere Pressemitteilungen dieses Herausgebers
- 08.01.2015 - Creathor's portfolio company Phenex Pharmaceuticals announces the acquisition of its development program for Non‐Alcoholic Steatohepatitis (NASH) and other liver diseases by Gilead Sciences, Inc., for up to $470m
- 08.01.2015 - Creathor's Portfoliounternehmen Phenex Pharmaceuticals AG gibt die Akquisition ihres Entwicklungsprogramms in NASH (Nicht‐Alkoholischer Steatohepatitis) und anderer Lebererkrankungen durch Gilead Sciences in Höhe von bis zu USD 470 Mio. bekannt
- 06.08.2014 - cloudControl, a Portfolio Company of Creathor Venture, acquires dotCloud PaaS business from Docker, Inc.